Alvotech, Bioventure obtain approval for Humira biosimilar in Egypt

Bioventure will be promoting AVT02 under the brand name Adalimumab-EVA.

Alvotech and Bioventure have received authorization from the Egyptian Drug Authority to manufacture and distribute AVT02 (adalimumab), a biological product similar to Humira.

The item effectively addresses rheumatoid arthritis as well as various other inflammatory conditions.

AVT02 will be promoted as Adalimumab-EVA in Egypt.

AVT02, a type of antibody known as a monoclonal antibody, has also received authorizations in various parts of the world, such as the European Union, the United Kingdom, Saudi Arabia, and Australia.

Robert Wessman, the chairman and CEO of Alvotech, expressed his satisfaction with the approval of AVT02 in Egypt.

Alvotech aims to enhance the availability of cost-effective biologics to patients globally, and this achievement signifies a significant step forward in our collaboration for the Middle East and North Africa (MENA) region.

Bioventure acts as the main ally of Alvotech, supporting them in promoting AVT02 and various other biosimilar candidates in the MENA regions.

Alvotech takes on the task of creating and manufacturing the product, while Bioventure takes care of promoting and selling it.

At present, the businesses are actively promoting AVT02 with the trademark Simlandi, after receiving official approval in January 2023.

Bioventure's CEO, Ashraf Radwan, expressed his unwavering dedication to improving healthcare accessibility and enhancing patient welfare. Today, we are commemorating a significant achievement as Bioventure and Alvotech rejoice in the approval of AVT02 in Egypt.

"At Bioventure, we are committed to creating and improving offerings that elevate the well-being of individuals, propelled by our goal of enabling universal access to the advantages offered by biotechnology."